Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solnatide in Acute Lung Injury
NCT01627613Phase 2Completed
- Sponsor
- APEPTICO
- Start
- Jul 2012
- Primary completion
- May 2014
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of solnatide in acute lung injury (ALI), sponsored by APEPTICO. Started Jul 2012; status: completed.
02
Drugs
solnatide
03
Conditions
acute lung injury (ALI)
Beyond the preview
Go deeper on NCT01627613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01627613.